首页> 外文期刊>Alimentary pharmacology & therapeutics. >Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial.
【24h】

Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial.

机译:纳多洛尔和单硝酸5-异山梨酯与内镜下结扎加硬化疗法预防肝硬化患者静脉曲张再出血的比较研究:一项随机对照试验。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: After variceal bleeding, cirrhotic patients should receive secondary prophylaxis. AIM: To compare nadolol plus 5-isosorbide mononitrate (5-ISMN) with endoscopic band ligation. The end points were rebleeding, treatment failure and death. METHODS: One hundred and nine cirrhotic patients with a recent variceal bleeding were randomized: nadolol plus 5-ISMN in 57 patients and endoscopic band ligation in 52 patients. RESULTS: The mean follow-up was 17 and 19 months in nadolol plus 5-ISMN and endoscopic band ligation groups, respectively. No differences were observed between groups in upper rebleeding (47% vs. 46%), variceal rebleeding (40% vs. 36%), failure (32% vs. 22%), major complications (7% vs. 13.5%) and death (19% vs. 20%), respectively. The actuarial probability of remaining free of rebleeding, failure and deaths were similar in both groups. Time to rebleeding shows that endoscopic band ligation patients had an early rebleed, with a median of 0.5 month (95% CI: 0.0-4.2) compared with patients from nadolol plus 5-ISMN, 7.6 months (95% CI: 2.9-12.3, P < 0.013). Multivariate analysis indicated that outcome-specific predictive factor(s) for rebleeding was Child A vs. B + C (P < 0.01); for failure was Child A vs. B + C (P < 0.02); and for death ascites (P < 0.01) and rebleeding (P < 0.02). CONCLUSION: This trial suggests no superiority of endoscopic band ligation over nadolol plus 5-ISMN mononitrate for the prevention of rebleeding in cirrhotic patients.
机译:背景:静脉曲张破裂出血后,肝硬化患者应接受二次预防。目的:比较纳多洛尔和5-硝酸异山梨酯(5-ISMN)与内镜下结扎术的比较。终点是再出血,治疗失败和死亡。方法:119例肝硬化患者近期曲张静脉出血被随机分配:纳多洛尔联合5-ISMN治疗57例,内镜下结扎术52例。结果:纳多洛尔联合5-ISMN和内镜带结扎组的平均随访时间分别为17个月和19个月。两组之间在上部再出血(47%vs. 46%),静脉曲张再出血(40%vs. 36%),衰竭(32%vs. 22%),主要并发症(7%vs. 13.5%)和死亡(分别为19%和20%)。两组中没有再出血,失败和死亡的精算机率相似。再出血时间表明,内镜带结扎患者的再出血较早,中位数为0.5个月(95%CI:0.0-4.2),而纳多洛尔和5-ISMN患者的中位数为7.6个月(95%CI:2.9-12.3, P <0.013)。多因素分析表明,再出血的结局特异性预测因子是Child A vs. B + C(P <0.01);失败的原因是儿童A vs. B + C(P <0.02);死亡腹水(P <0.01)和再出血(P <0.02)。结论:该试验提示内镜带结扎术在预防肝硬化患者再出血方面没有优于纳多洛尔和5-ISMN一硝酸盐的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号